Search

everythinglearnresearchcommunity

for

Search:↓

Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.

The new adapalene formulation using TyroSpheres is more effective and less irritating for acne treatment.

A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.

UVFD can help doctors better identify harmful skin lesions on the face, reducing unnecessary biopsies.

Dutasteride-containing mesotherapy effectively treats female hair loss, improving density and thickness with minimal side effects.

D-OCT shows increased blood vessel growth in response to tissue damage in Frontal Fibrosing Alopecia and is useful for diagnosis and monitoring.

Use a 3-mm spot size and specific protective eyewear for safer and more effective laser treatment of facial veins.

Etretinate treatment changed hair growth patterns in many patients.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Mackerel fermented fish oil protects skin cells from damage by UVB light.

Topical rapamycin may effectively treat fibrous papules on the face.

Nail loss may be a side effect of the MS drug teriflunomide.

Genetic differences affect breast cancer treatment success with tamoxifen in South African patients.

Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.

Temporal triangular alopecia is a lifelong condition with hairless patches on the side of the head that may be present from birth.

Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.

New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.

New treatment with green tea polyphenols and nicotinamide improves skin problems from cancer therapy.

Gefitinib can cause scalp skin issues and permanent hair loss.

Ultraviolet light treatment with trioxsalen was ineffective for vitiligo in the cases described.

Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.

Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.

Oral tofacitinib is more effective than oral minoxidil for treating alopecia areata.

EGFR inhibitors often cause dry, brittle hair and eyebrow/eyelash changes.

The woman's widespread skin condition did not improve despite various treatments.

The patient has frontal fibrosing alopecia (FFA).

Topical flutamide works as well as hydroquinone for melasma but needs more safety checks.